Trials / Completed
CompletedNCT00256399
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
A Prospective, Open Label, Study to Assess the Efficacy of Alfuzosin 10 mg Tablet Once a Day in Male Subjects Suffering From Benign Prostate Hypertrophy Associated Lower Urinary Tract Symptoms and Erectile Dysfunction
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University Hospitals Cleveland Medical Center · Academic / Other
- Sex
- Male
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.
Detailed description
The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The total duration of the study will be 120 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfuzosin 10 mg |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-05-08
- Completion
- 2007-05-08
- First posted
- 2005-11-21
- Last updated
- 2022-08-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00256399. Inclusion in this directory is not an endorsement.